Table 4.
Vaccine effectiveness (VE) against infection of any severity after the second dose of BNT162b2 (Pfizer-BioNTech) across all SARS-CoV-2 variants. The numbers only reflect VE against infection, independent of symptoms. Adjusted VE was calculated using a logistic regression model with adjustment for age, comorbidity, health worker status, and age-adjusted average incidence in the German population during the time frame of interest. Unadjusted VE was calculated using the Farrington screening method.
| Weeks after second vaccine dose | Sample size, n | Cases (positive PCRa test), n (%) | Adjusted VE (logistic regression; %, 95% CI) | Unadjusted VE (Farrington method; %, 95% CI) | |
|
|
|
Vaccinated individuals | Unvaccinated individuals |
|
|
| 4 | 1679 | 3 (0.2) | 33 (2) | 91.2 (70.4 to 97.4) | 90.9 (70.4 to 97.2) |
| 8 | 1680 | 17 (1) | 55 (3.3) | 72 (50.1 to 84.3) | 69.1 (46.8 to 82.1) |
| 12 | 1679 | 32 (1.9) | 79 (4.7) | 66.8 (47.2 to 79.1) | 59.5 (38.9 to 73.1) |
| 16 | 1678 | 49 (2.9) | 113 (6.7) | 63.3 (46.5 to 74.8) | 56.6 (39.4 to 69) |
| 20 | 1680 | 78 (4.6) | 142 (8.5) | 50.4 (23.1 to 63.7) | 45.1 (27.6 to 58.3) |
| 24 | 1658 | 118 (7.1) | 184 (11.1) | 42.3 (24.7 to 55.8) | 35.9 (19.2 to 49.1) |
| 28 | 1559 | 174 (11.2) | 187 (12) | 2.5 (−23.8 to 23.1) | 7 (−14.4 to 24.3) |
| 32 | 1446 | 213 (14.7) | 241 (16.7) | 10.4 (−11.5 to 28) | 11.6 (−6.3 to 26.5) |
| 36 | 1391 | 219 (15.7) | 272 (19.6) | 21.3 (2.7 to 36.3) | 19.5 (3.8 to 32.6) |
| 40 | 1355 | 231 (17) | 309 (22.8) | 31.1 (15.5 to 43.8) | 25.2 (11.3 to 37) |
| 44 | 1314 | 238 (18.1) | 320 (24.4) | 30.2 (14.8 to 42.8) | 25.6 (12 to 37.1) |
| 48 | 1319 | 233 (17.7) | 343 (26) | 37.2 (23.5 to 48.5) | 32.1 (19.8 to 42.5) |
aPCR: polymerase chain reaction.